Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Targeting insulin-like growth factor axis in hepatocellular carcinoma"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Targeting insulin-like growth factor axis in hepatocellular carcinoma. | Wu and Zhu Journal of Hematology Oncology 2011 4 30 http www.jhoonline.Org content 4 1 30 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Targeting insulin-like growth factor axis in hepatocellular carcinoma Jennifer Wu1 and Andrew X Zhu2 Abstract The insulin-like growth factor IGF axis contains ligands receptors substrates and ligand binding proteins. The essential role of IGF axis in hepatocellular carcinoma HCC has been illustrated in HCC cell lines and in animal xenograft models. Preclinical evidence provides ample indication that all four components of IGF axis are crucial in the carcinogenic and metastatic potential of HCC. Several strategies targeting this system including monoclonal antibodies against the IGF 1 receptor IGF-1R and small molecule inhibitors of the tyrosine kinase function of IGF-1R are under active investigation. This review describes the most up-to-date understanding of this complex axis in HCC and provides relevant information on clinical trials targeting the IGF axis in HCC with a focus on anti-IGF-1R approach. IGF axis is increasingly recognized as one of the most relevant pathways in HCC and agents targeting this axis can potentially play an important role in the treatment of HCC. Introduction Hepatocellular carcinoma HCC is the 5th most common neoplasm worldwide with more than 600 000 cases per year and the 3rd leading cause of cancer-related death 1 2 . For the past 3 decades the incidence of HCC in the US has tripled yet the 1 year survival rate of HCC remains less than 50 3 . Currently sorafenib is the only medication that shows overall survival advantage compared to placebo in patients with advanced HCC 4 5 . However the benefits with sorafenib are moderate and its toxicities can be challenging to manage. For patients who fail or cannot tolerate sorafenib there are currently no standard treatments. Therefore there is an urgent need to search for novel effective therapies in advanced HCC. Recently the insulin-like growth factor .